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The International Myopia Institute’s (IMI) mission is to advance research, education, and
management of myopia to decrease future vision impairment and blindness associated
with increasing myopia. Its approach is to bring together scientists, clinicians, policymak-
ers, government members, and educators into the field of myopia to stimulate collabora-
tion and sharing of knowledge. The latest reports are on pathologic myopia, the impact of
myopia, risk factors for myopia, accommodation and binocular vision in myopia devel-
opment and progression, and the prevention of myopia and its progression. Together
with the digest updating the 2019 International Myopia Institute white papers using the
research published in the last 18 months, these evidence-based consensus white papers
help to clarify the imperative for myopia control and the role of environmental modifi-
cation initiatives, informing an evidence-based clinical approach. This guidance includes
who to treat and when to start or stop treatment, and the advantages and limitations of
different management approaches.
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Public health is defined as “the art and science of prevent-ing disease, prolonging life and promoting health
through the organized efforts of society.”1 Myopia has a
major impact on eye health and hence quality of life and
disability, particularly later in life, owing to its association
with both direct and indirect damage to the chorioretina,
optic nerve, and the crystalline lens.2 The global burden of
myopia is growing, with nearly 30% of the world popula-
tion currently myopic and an expectation that this number
may increase to nearly one-half of the world’s population
in 2050.3 Over this time period, approximately 10% of the
world’s inhabitants will have high myopia, translating to
nearly 1 billion people.3 Uncorrected myopia is the most
common cause of avoidable distance visual impairment, and
myopic macular degeneration has already become the lead-
ing cause of uncorrectable vision loss in some parts of the
world.4
Although pathologic myopia is associated with higher
degrees of myopic refractive error (see the International
Myopia Institute [IMI] Pathological Myopia Report),5 its
complications, especially posterior staphyloma, can also
occur in eyes with lower degrees of myopia. There are no
distinct cut-off values for refractive error or axial length
when pathology occurs; rather, any increase in axial length
in a myopic eye (with associated change in refractive error)
increases the risk of pathology.2 The assumption that inter-
ventions in childhood myopia progression will decrease the
prevalence of pathologies later in life is unsubstantiated
(but likely),6 owing to the lack of data charting the long-
term course between childhood myopia progression and the
onset of pathologic changes such as myopic maculopathy.
Myopia-associated pathologies also vary with patient char-
acteristics such as sex, ethnicity, and the level of myopia,7,8
confounding direct associations without longitudinal data.
It has been hypothesized that the stimulus for the current
myopia epidemic, particularly the increase in the preva-
lence and degree of common childhood myopia, is due to
ongoing changes in our behavior and environment, rather
than being driven genetically. Genetic and prevalence data
suggest that extreme myopia has a different origin than
the more commonly seen childhood myopia, which is most
likely largely driven environmentally.9–11 In this respect,
studies already demonstrate a strong association between
the level of refractive error and myopic maculopathy across
a wide range of myopic refractive errors,7,8 and recent 6- and
12-year prospective longitudinal studies from Japan reported
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significant increases in the prevalence of different levels
of myopia and associated pathology.12,13 Hence, the inci-
dence of myopia-related ocular complications and perma-
nent vision impairment is very likely to significantly increase
alongside the growing prevalence of myopia globally.3
The IMI Impact of Myopia Report14 summarizes recent
research on the increasing prevalence of myopia, including
the disproportionally greater increase in high myopia and
the lifetime manifestations of myopia. In addition, it high-
lights the considerable direct health expenditures and indi-
rect costs such as lost productivity and reduced quality of
life associated with myopia.
ENVIRONMENTAL MODIFICATION
The IMI Risk Factors for Myopia Report15 identifies the diffi-
culties in “untangling” the risk factors for the development
and progression of myopia from current research; however,
education and time spent outdoors were identified as the key
factors. They conclude that there is a large body of consistent
evidence of a causal association between the higher preva-
lence and degree of myopia with an increasing intensity and
duration of education, but the mechanism involved is still
unclear. The current evidence implicating digital devices is
sparse and far from consistent. No interventions in decreas-
ing nearwork have been validated in controlled trials. Strong
evidence has been accumulated for time spent outdoors
(principally lighting levels) decreasing the prevalence and
progression of myopia,16–19 possibly owing to dopamine
release, decreasing the impact of other risk factors such as
parental myopia20 and higher levels of nearwork.21 School-
based intervention trials have shown that an increase in time
outdoors of 40 to 80 minutes per day produces a signifi-
cant decrease in the incidence of myopia.22–24 Interestingly,
one study suggested modest increases in class-room lighting
strongly inhibited the development of myopia,25 but replica-
tion of this finding is needed.
It should be noted that, unlike other epidemics, such as
the increase in obesity and diabetes, myopic environmen-
tal risk factors are driven largely by a desire to improve the
prospects of children and the quality of life of nations, by
increasing the level of education. In addition, the success of
less divisive public health programs to decrease obesity and
diabetes has been limited26,27; hence, national public health
programs focused on decreasing the impact of myopia by
environmental modifications alone cannot be relied on to
decrease significantly the impact of myopic epidemic, and
eye care practitioners have a key role in improving the
future eye health of their patients including providing holis-
tic advice about increasing time spent outdoors.
AN EVIDENCE-BASED CLINICAL APPROACH
Who to Treat and When to Start
The IMI have defined premyopia as “A refractive state of
an eye of ≤ +0.75 D and > –0.50 D in children where a
combination of baseline refraction, age, and other quan-
tifiable risk factors provide a sufficient likelihood of the
future development of myopia to merit preventative inter-
ventions.”28 A cycloplegic refraction should be performed
to avoid misclassification,29 unless the practitioner can be
assured the eye is unaccommodated.30,31 Premyopia can be
predicted as early as 6 years of age by a refractive error of
<+0.75 diopters [D] (<+0.50 D in a 7- to 8-year-old child;
<+0.25 D in a 9- to 10-year-old child; and emmetropia in
an 11-year-old child) with a high degree of confidence.32
Although the number of myopic parents is a risk factor for
myopic progression (odds ratio in 6- to 8-year-olds: 1.4×
for 1 parent and approximately 2.3× for 2 parents), along
with harder to measure ocular biometry factors such as the
AC/A ratio (approximately 1.25×), axial length (2.0–2.5×)
and peripheral refraction (1.4×), a study found refractive
error alone best predicts the risk of future myopia.32 A recent
study in the UK also found axial length (>23.07 mm) at base-
line (odds ratio, 2.5×) at the age of 6 years and at least one
myopic parent (odds ratio 6.3×) as predictive of progres-
sion to myopia by age 16 years along with a refraction
of <+0.63 D.33 Although binocular vision status is impor-
tant in children to optimize visual clarity and minimize eye
strain, and therefore should be assessed and managed if
necessary, evidence for any role in myopia development
and progression is limited (see the IMI Accommodation and
Binocular Vision in Myopic Development and Progression
report).34
Management Approach
Advising on maximizing time spent outdoors is good for
all children’s general mental health35 as well as decreasing
the incidence and progression of myopia,16–19 especially in
winter when myopic progression is greater.36 However, as
identified elsewhere in this article, this factor will have a
limited effect on decreasing the incidence of myopia or its
progression in those who are already myopic owing to soci-
etal factors. For those who have premyopia, or who have
low myopia (<–0.5 D), a refractive correction would not be
suitable so advice should be given as to the need for regu-
lar eye examinations and to prepare the patient and their
parents/carers. If there is ≥–0.50 D of myopia, in consulta-
tion with the child´s caregiver, consideration for a refractive
and/or pharmaceutical correction should be considered (see
the IMI Prevention of Myopia and Its Progression report)37
• Orthokeratology – effective from –0.50 to –4.00
D38,39 and up to –3.50 D of astigmatism,40 and can
be used in conjunction with an optical correction
worn during the day for higher myopia (>6.0 D).41
However, it requires overnight contact lens wear with
its associate risks of microbial keratitis.42 A desire for
children to be free of a refractive correction during
the day is key in the success of orthokeratology.43
• Soft myopia control multifocal contact lenses – effec-
tive commercially available lenses are now on the
market in a wide range of powers. Up to 6 years
of clinical trials demonstrate good safety and effi-
cacy.44–48 Daily disposable modality has a risk of
microbial keratitis of about 10× less than that of
orthokeratology treatment.49
• Myopia control spectacle lenses – have become
commercially available with variable efficacy
reported with data for up to 2 years in clinical
trials, but there has been limited research conducted
to date.50,51
• Atropine – the most appropriate dose has yet to be
determined, but based on current research is within
the range 0.01% to 0.05%52,53; however, the use of a
pharmaceutical depends on the availability and risks,
which include untested long-terms effects.
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• Combination therapy seems to be more effective
than a single treatment approach, and so should be
considered if myopic progression continues.54,55
• Sequential treatment modalities – the effectiveness
of current treatments appears to decrease with
time, providing approximately a cumulative maxi-
mum approximately 1.0 D decrease in refractive
error or approximately +0.44 mm decrease in axial
length.6,56 However, treatment modalities seem to
have differing mechanisms of action, so it is possible
that using different modalities sequentially may have
a greater cumulative effect, although this has yet to
be researched.
It has been argued that, to monitor myopic progression,
axial length is a more reliable measure than even cyclo-
plegic refractive error and it is the principal risk factor
for myopia-associated pathology.6 However, instrumenta-
tion using partial coherence interferometry/optical coher-
ence tomography or optical low coherence reflectometry
(essentially the same technique, but using a laser or a super-
luminescent diode respectively) which have a suitable reso-
lution of approximately 0.01 mm or <0.05 D,57 are still
relatively expensive and not yet commonplace in clinical
practice.
When to Stop
There are few data on when myopia stops progressing.
Progression has been noted in young adults58 and approxi-
mately one-third of myopia adults only develop myopia after
15 years of age.59 The mean age of refractive error stabiliza-
tion for early childhood onset myopic seems to be around
16 years of age (perhaps about 1 year younger in females
than males),60,61 but there is considerable variability. Axial
length seems to take much longer to stabilize, with 90%
stabilizing by 21 years of age in one longitudinal study.60,62
Hence, careful monitoring of patients after ceasing treatment
is prudent. Fortunately, in controlled trials, a clinically signif-
icant rebound effect has only been observed after ceasing
higher dose atropine treatment63,64 and perhaps in young
children with orthokeratology.65
CONCLUSIONS
There is more than sufficient evidence to warrant the adop-
tion of myopia prevention and control measures in clinical
practice. Although there remain gaps in academic knowl-
edge about mechanism of action and long-term outcomes,
the benefits outweigh the risks if they are appropriately
managed.66 More research on the effectiveness and safety
of combination and sequential treatment modalities would
further enhance patient management options. Eye care prac-
titioners have a key role to play in preventing visual impair-
ment in future generations and must become more proac-
tive67 in the identification and treatment of myopia.
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